Abstract 216P
Background
Wilms tumor (WT) is a rare kidney cancer, but it is the most common malignant tumor of the kidneys of children. Although radical nephroectomy has been viewed as the gold standard surgery in Wilms tumor management for many years, partial nephrectomy has gained a lot of attention recently. So we conducted this study to compare the long term overall survival between those two different surgical techniques.
Methods
Using SEER database, we extracted the data of 636 patients with WT from 2000 to 2006. There were 55 (8.6%) patients underwent partial nephrectomy, while 581 (91.4%) of them underwent radical nephrectomy. Patients’ demographics were assessed.
Results
Our study showed that there is NO significant difference in Long-Term overall survival between partial nephrectomy and radical nephrectomy, where overall 10-year relative survival rates were 92.6% and 88.1%, respectively (p value =0.240). Subgroup analysis revealed NO significant difference in overall survival Except in patients with different age groups as seen in the table (p value <0.0001) but this could have been caused by the fact that few patients were recorded.
Table: 216P
Variables | Survival of Patients | p value | |
---|---|---|---|
Partial nephroectomy | Radical nephroectomy | ||
Sex Male Female | 96 % 89.7 % | 87.9 % 88.3 % | 0.821 |
Age 0- 9 10-19 20-39 40-59 60-79 | 91.5% 100%** 100%** 100%** 100%** | 89.9% 71.8% 36.4% 100% 66.7% | <0.0001*** |
Race White | 91% 100% _* % _* % | 88.8% 86.1% 88.9% 83.3% | 0.574 |
Black American Indian/Alaska Asian/pacific Islander | |||
Laterality Right left Bilateral | 89.9% 92.9% 95% | 90.1% 85.8% 92% | 0.175 |
Highly significant P-value ≤ 0.001.
**few no. of cases _.
*no recorded patients.
Conclusions
There is NO significant difference in overall 10-year survival between partial nephrectomy and radical nephrectomy. So, we recommend the application of partial nephrectomy in the appropriate patients to preserve as much kidney tissue and function as possible especially in bilateral WT. Further studies should be conducted on larger number of patients and they should study the efficacy of chemotherapy in patients undergoing partial nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mira Mohamed Mostafa.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract